We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 11 for:    genomic health prostate | Completed Studies
Previous Study | Return to List | Next Study

Study In Urology Practices Looking At Impact Of OncotypeDX GPS Test On Men Choosing And Remaining On Active Surveillance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03502213
Recruitment Status : Completed
First Posted : April 18, 2018
Last Update Posted : April 23, 2021
Information provided by (Responsible Party):
Genomic Health®, Inc.

Brief Summary:
Genomic Health's OncotypeDX® Prostate Cancer Assay is a commercially available laboratory test that measures the activity of certain genes in prostate cancer. The purpose of this study is to better understand how the use of this test result impacts or affects treatment decisions for men newly diagnosed with low risk prostate cancer, their confidence in the treatment decision, and the effects and side effects of the treatment chosen on certain aspects of Quality of Life. This study will also determine what percentage of men choosing an active monitoring program as prescribed by their doctor remain on Active Surveillance and have avoided any treatment at one year after diagnosis after receiving the assay result.

Condition or disease
Prostate Cancer

Detailed Description:

This is a multicenter observational study that evaluates eligible patients who will submit prostate cancer diagnostic biopsy tissues for Oncotype DX Prostate Cancer Assay testing. A physician treatment recommendation will be made and the assay is ordered. The physician will review clinical data, the GPS report and discuss treatment options with the patient. At the following visit, a shared physician-patient treatment decision (immediate treatment or AS) will be made.

Men selecting AS as primary treatment will be followed to assess persistence on AS.

There is no required or standardized AS protocol for this study and the intensity of surveillance will be at the discretion of the investigator. Patients will not be required, but may undergo a standard TRUS guided surveillance biopsy at one year. In this study, the Oncotype DX Prostate Cancer Assay will be assessed on the diagnostic biopsy only and will not be assessed on subsequent biopsies.

Layout table for study information
Study Type : Observational
Actual Enrollment : 489 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective Multi-center Observational Trial to Assess Persistence on Active Surveillance When Using the OncotypeDX® Prostate Cancer Assay
Actual Study Start Date : July 1, 2014
Actual Primary Completion Date : June 30, 2018
Actual Study Completion Date : June 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Primary Outcome Measures :
  1. Rate of persistence on Active Surveillance at 1 and 2 years after receiving the OncotypeDX Genomic Prostate Score (GPS) [ Time Frame: The analysis will estimate the absolute magnitude of the rates of persistence at these two time points (1 and 2 years after receiving GPS) ]
    The analysis will estimate the absolute magnitude of the rates of persistence at these two time points, and the change between the two rates. The rate of persistence, at the particular timepoint, will be calculated as the proportion of patients who remain on Active Surveillance as of the doctor visit at the time. The rate of persistence will range from 0% to 100%, with 100% indicating all evaluable patients stay on Active Surveillance at the particular timepoint, and 0% indicating no evaluable patient on Active Surveillance.

Biospecimen Retention:   Samples With DNA
fixed paraffin embedded tissue (FFPE) blocks [retained up to 2 years], FFPE sectioned slides [retained up to 2 years], unstained slides [retained up to 2 years], and/or RNA [retained up to 20 years].

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Newly diagnosed with prostate cancer within the last 3 months, with no treatment decision having been made.

Inclusion Criteria:

  • Clinical stage T1c/T2
  • PSA ≤ 20ng/mL
  • Biopsy GS ≤ 6 with any number of cores positive, or Biopsy GS 3+4 disease with ≤3 positive cores or ≤ 33% positive cores
  • The patient must be ≥ 50 years of age
  • The patient must have a life expectancy of > 10 years
  • Patient must be able to give consent in English or Spanish

Exclusion Criteria:

  • Clinical stage T3a or above
  • PSA > 20ng/mL
  • Biopsy GS 4+3 or > 8
  • Known metastatic prostate cancer
  • Positive biopsy for prostate cancer > 3 months ago
  • Treatment decision has already been made
  • Insufficient tumor in prostate biopsy tissue to perform the assay
  • Treatment with androgen deprivation therapy (ADT) prior to prostate biopsy
  • Diagnosis made by transurethral resection of prostate (TURP) shavings
  • Any psychiatric or psychological conditions
  • Contraindications to primary treatment according to physician's judgment
  Study Documents (Full-Text)

Documents provided by Genomic Health®, Inc.:
Layout table for additonal information
Responsible Party: Genomic Health®, Inc.
ClinicalTrials.gov Identifier: NCT03502213    
Other Study ID Numbers: 09-023
First Posted: April 18, 2018    Key Record Dates
Last Update Posted: April 23, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Genomic Health®, Inc.:
Prostate Cancer
Localized Prostate Cancer
Low Risk Prostate Cancer
Active Surveillance
Active Monitoring
OncotypeDX GPS
Genomic Prostate Score
Genomic Test
Molecular Test
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Prostatic Diseases
Male Urogenital Diseases